A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
Revolution Medicines, Inc.
Seagen Inc.
Eli Lilly and Company
Pfizer
UMC Utrecht
Pfizer
A2 Biotherapeutics Inc.
Revolution Medicines, Inc.
H. Lee Moffitt Cancer Center and Research Institute
University of Colorado, Denver
City of Hope Medical Center
University of Nebraska